02.03.2010 - Shionogi enters into exclusive license agreement with Quatrx Pharmaceuticals to market Ospemifene
02 Mar 2010
02.03.2010 Shionogi enters into exclusive license agreement with quatrx pharmaceuticals to market ospemifene
Shionogi Limited. Registered in England and Wales No. 07945432. Registered office: 33 Kingsway. London WC2B 6UF, UK.
Report Side Effect
Just to let you know, you are now moving to another website this is not under our control and Shionogi Limited is not responsible for its contents.